ArticleBMC cancer2025
Development and validation of a predictive model for recurrence in postoperative patients with stage ⅠA1-ⅢA non-small cell lung cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPatients of non-small cell lung cancer (NSCLC) face a high risk of recurrence postoperatively, yet there is a lack of comprehensive predictive models that integrate genetic and other multifaceted information.
methodsThis retrospective cohort study analyzed 911 patients with stage ⅠA1-ⅢA NSCLC in West China Hospital between November 2013 and August 2020, aimed to develop a prediction model incorporating demographic, clinical, pathological, radiological, and genetic data to enhance postoperative risk stratification and inform personalized follow-up and treatment strategies. After Lasso regression and multivariate Cox proportional hazards regression, mutations in JAK1 and STK11, disease stage, visceral pleural invasion (VPI), lymphovascular invasion (LVI), tumor spread through air spaces (STAS), radiological density, cavitary sign, and smoking index (SI), were identified as significant risk factors.
resultsThese variables were integrated into a nomogram model to classify patients into three risk categories for recurrence: low (total score ≤ 100), moderate (100 < total score ≤ 175.16), and high (total score > 175.16). The performance of the nomogram was rigorously assessed through calibration curves, and decision curve analysis (DCA) and receiver operating characteristic (ROC) curve analysis both in training set [AUC:0.88, 95% CI: 0.83-0.93 1year; AUC: 0.85, 95% CI: 0.81-0.89r 3year, AUC: 0.85, 95% CI: 0.81-0.895year] and validation set (AUC: 0.85, 95% CI: 0.79-0.92 1year; AUC: 0.83, 95% CI: 0.76-0.89 3year, AUC: 0.84, 95% CI: 0.78-0.91 5year).
conclusionsOur multi-source imaging-genomic-clinical model accurately predicts the risk of recurrence after surgery in stage ⅠA1-ⅢA NSCLC patients and can be used for risk stratification to guide clinical follow-up management and postoperative treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.